Drug intelligence / Profile preview

SIR-X4

Development stage: Unknown
Lead developer: Sironax

Overview

SIR-X4 is a discovery-stage therapeutic candidate being developed by Sironax, a biotechnology company focused on age-related and neurodegenerative diseases. As of early 2024, SIR-X4 is listed in the company's pipeline as an early-stage asset with no publicly disclosed biological target, molecular modality, or specific therapeutic indication. Sironax's broader research platform centers on pathways involved in programmed cell death (such as necroptosis) and axonal degeneration, but the specific mechanism of SIR-X4 remains proprietary.

Other names: SIR-X4-SironaxSIR-X-4-SironaxSIR-X 4-Sironax

Beyond the preview

Go deeper on SIR-X4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-X4.

Explore the full profile